Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the selective loss of motor neurons. Several susceptibility genes for ALS have been reported; however, ALS etiology and pathogenesis remain largely unknown. To identify further ALS-susceptibility genes, we conducted a large-scale case -control association study using gene-based tag single-nucleotide polymorphisms (SNPs). A functional SNP (rs2275294) was found to be significantly associated with ALS through a stepwise screening approach (combined P 5 9.3 3 10 210 , odds ratio 5 1.32). The SNP was located in an enhancer region of ZNF512B, a transcription factor of unknown biological function, and the susceptibility allele showed decreased activity and decreased binding to nuclear proteins. ZNF512B over-expression increased transforming growth factor-b (TGF-b) signaling, while knockdown had the opposite effect. ZNF512B expression was increased in the anterior horn motor neurons of the spinal cord of ALS patients when compared with controls. Our results strongly suggest that ZNF512B is an important positive regulator of TGF-b signaling and that decreased ZNF512B expression increases susceptibility to ALS.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a heterogeneous motor neuron disease that results from selective death of motor neurons in the brain and spinal cord (1) . The predominant clinical feature of ALS is progressive wasting and weakness of limb, bulbar and respiratory muscles. The mean survival of patients after onset of symptoms is 3 -5 years. Its worldwide incidence and prevalence are 0.3-2.4 and 0.7 -7.0 per 100 000 each year (2) . The heritability of ALS is high, with twin studies estimating it at 0.61 and the unshared environment component at 0.39 (3) .
Approximately 10% of ALS cases are familial (fALS), and the remaining 90% are sporadic (sALS). Genetic factors have been reported in ALS. Detailed information regarding ALS-related genes is available via amyotrophic lateral sclerosis online genetics database and the ALS mutation database (4, 5) . Most fALS is monogenic in origin. At least 15 fALS loci, under various modes of inheritance, have been identified by linkage studies, and pathogenic mutations have been described in 11 genes, SOD1, NEFH, ALS2, DCTN1, VAPB, SETX, ANG, TARDBP, FUS, OPTN and DAO, in fALS (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Despite the abundance of genes and loci identified in fALS, mutations in these genes explain only a small minority of sALS (20) .
Regarding susceptibility genes for sALS, .30 association studies based on the candidate-gene approach have been reported (21, 22) . Among them, NEFH, APEX and ANG have the most evidence; associations of these genes have been found in Caucasians (23) (24) (25) and replicated in several studies (7, 22, 26) . However, many of the reported genes are still controversial. For example, the association of nonsynonymous substitution (P413L) in the chromogranin B gene (CHGB) is reported in French, French-Canadian and Scandinavian ALS populations (27) , but has not been found in a Dutch and another French population (28, 29) .
The genome-wide association study (GWAS) has identified five ALS-susceptibility genes (FGGY, ITPR2, DPP6, KIFAP3 and UNC13A) and two loci (9p21.2 and 10q26.3) in Caucasian (30 -35) . These results are promising, but remain slightly controversial (36) (37) (38) (39) . The association of the 9p21.2 locus has been independently replicated in three studies (34, 40, 41) , but is not found in all populations, including those from Japan and China (42) . More studies are necessary to evaluate and confirm these previously reported ALS-susceptibility genes.
To identify novel susceptibility genes for ALS, we conducted a large-scale genetic association study in Japanese ALS patients using gene-based single-nucleotide polymorphisms (SNPs) (43) . We identified a functional SNP that was significantly associated with ALS. The SNP was located in an enhancer region of ZNF512B, a previously uncharacterized transcription factor, and the susceptibility allele of the SNP had decreased enhancer activity for the ZNF512B promoter and decreased binding capacity to nuclear proteins. We found that in neuron cells, ZNF512B acts as a positive regulator of transforming growth factor-b (TGF-b) signaling, which is known to be neuroprotective and critical for maintenance and/or survival of neurons (44) (45) (46) . We demonstrated the localization of ZNF512B in the spinal cord of ALS patients and it showed enhanced expression in motor neuron cells of the anterior horn when compared with controls.
RESULTS

Genome screening
We carried out a stepwise case -control association study (Supplementary Material, Fig. S1 ) as previously described (47) (48) (49) (50) (51) . In stage 1 of the discovery series, 92 ALS and 233 control subjects were analyzed at 52 608 gene-based SNP loci selected from the JSNP database (43) . Genotype information was successfully obtained for 48 939 SNPs on autosomal chromosomes passed after the quality control. Either the Chi-square test or Fisher's exact test was performed for three genetic models: dominant, recessive and allelic. Comparison of observed and expected distributions showed no evidence for inflation of the trend test statistics (inflation factor, lambda ¼ 1.04; Supplementary Material, Fig. S2 ). Also, principal component analysis (52) in stage 1 and HapMap samples showed no evidence of population stratification between the case and control groups (Supplementary Material, Fig. S3 ). In stage 2 of the discovery series, 893 SNPs that showed P-values of ≤0.01 in stage 1 were genotyped for an additional 1087 subjects (362 ALS cases and 725 controls). Subsequently, 10 SNPs with P-values ,0.001 were identified by the Chi-square test for the three models (Supplementary Material, Table S1 ).
Identification of genetic association between rs2275294 and ALS
We validated the association of these SNPs using independent subjects from Biobank Japan (sample set 1). In all, 249 ALS cases and 1030 controls were genotyped and validated the association in rs2275294 (allele model, P ¼ 1.8 × 10
23
).
The SNP was then genotyped in an independent Japanese population consisting of 602 ALS cases and 2256 controls (sample set 2). Significant association was replicated in this population (allele model P ¼ 5.6 × 10 25 ). The combined P-values for the stepwise association study calculated by the Mantel-Haenszel method and the joint analysis were 9.3 × 10 210 and 6.7 × 10
210
, respectively ( Table 1 ). The combined P-values remained significant after Bonferroni correction (9.3 × 10 210 × 52 608 × 3 ¼ 1.47 × 10 24 ). The P-values from the Mantel -Haenszel method and the joint analysis were very similar, supporting the fact that there is no hidden confounder in our population. The minor allele frequency (MAF) of rs2275294 in 744 samples of the Japan Biological Informatics Consortium (JBIC)-genotyping data deposited in the dbSNP database was similar to that of our controls (0.414).
Evaluation of rs2275294
We assessed the stratification using principal component analysis (52) . The top six principal components were associated with case -control status. The association of rs2275294 with the top six principal components included as covariates (trend model P ¼ 0.00287) was similar to that in stage 1 (trend model P ¼ 0.00246), suggesting no stratification. Population stratification was also assessed by evaluating differences in population structure among all case and control sample sets using Wright's F statistics (53) . There was no difference in the population structure among these groups (Supplementary Material, Table S2 ). Potential confounding factors were also examined and no significant differences in age and gender distribution were found among rs2275294 genotyped. The associations with rs2275294 were significant in two sample sets (P ¼ 4.1 × 10 23 and 1.4 × 10
24
), even after adjusting for age and gender in a logistic regression analysis.
Genome analysis of the ALS critical region containing rs2275294
We constructed a linkage disequilibrium (LD) map around rs2275294 on the basis of the genotyping data for Japanese subjects used in HapMap (HapMap JPT). Because rs2275294 was unmapped in the HapMap data, we genotyped the SNP for the HapMap JPT samples and integrated the data with the HapMap JPT data. We found that rs2275294 was in strong LD with the two SNPs rs6122232 and rs3764736 (D ′ . 0.85). Subsequently, the critical region could be confined to a 111 kb interval flanked by rs2252258 and rs816953 on chromosome 20q13.33 ( Fig. 1 ). This region included four genes (ZNF512B, SAMD10, PRPF6 and SOX18) and a part of UCKL1, as well as two non-proteincoding RNAs (UCKL1OS and NCRNA00176). In order to identify a more significantly associated SNP, we searched for SNPs in each gene by re-sequencing genomic DNA of 48 ALS subjects. A total of 24 SNPs were identified and their level of association was examined using 455 cases and 452 controls, but rs2275294 remained the most significantly associated (Supplementary Material, Table S3 ).
Functional analysis of rs2275294
To gain insight into the biological significance of rs2275294, luciferase reporter plasmids corresponding to a genomic DNA fragment containing rs2275294 were constructed and a luciferase assay using the human neuroblastoma cell line SK_N_Be(2)C was performed. Constructs containing the ALS-susceptibility allele (C allele) of rs2275294 showed lower enhancer activity than those containing the nonsusceptibility allele, indicating that the SNP affects the ZNF512B transcription level ( Fig. 2A) . We then examined the allelic difference in the binding of genomic DNA containing rs2275294 to nuclear proteins by the electrophoretic mobility shift assay (EMSA). The DNA -protein complex from the C allele showed weaker binding (Fig. 2B ). Thus, it is feasible that the presence of the susceptibility allele leads to lower ZNF512B levels as a consequence of decreased enhancer activity.
ZNF512B is a positive regulator in the TGF-b signaling pathway
Proteomics analysis has suggested that ZNF512B functions as a regulator of the TGF-b signaling pathway (54) . We examined the effect of ZNF512B on TGF-b signaling using the TGF-b-dependent SMAD2/3-specific luciferase assay (55) in a HepG2 cell (data not shown). SMAD2/3-mediated reporter activity after TGF-b stimulation was enhanced by ZNF512B over-expression. The TGF-b-dependent reporter activity was activated by ZNF512B over-expression in a neuroblastoma cell line SK_N_AS (Fig. 3A ) and a glioblastoma cell line U87MG (Supplementary Material, Fig. S4 ). Next, we knocked down expression of the endogenous ZNF512B in SK_N_AS by using the short-interfering RNA (siRNA) technique. Real time polymerase chain reaction (PCR) showed that ZNF512B siRNA significantly reduced ZNF512B transcription, and TGF-b-dependent reporter activity was repressed by the siRNA (Fig. 3B ).
ZNF512B expression in the spinal cord of ALS
The localization of ZNF512B in the spinal cord of ALS patients was investigated by immuno-histochemical studies. The immuno-reactivity for an anti-ZNF512B polyclonal antibody was intense in motor neuron cells in the anterior horn of the spinal cords of ALS patients, while it was barely detectable in those of controls ( Fig. 4A -D) . Glial cells in the anterior horn did not show ZNF512B immuno-reactivity.
DISCUSSION
By a large-scale case-control association study using genebased SNPs and enrolling a total of more than 5500 subjects, we identified ZNF512B at chromosome 20q13.33 as a new susceptibility gene for ALS. rs2275294 in ZNF512B had significant association that satisfied a genome-wide significance level (P ¼ 9.3 × 10
210
). rs2275294 affected ZNF512B transcription in vitro, and the ALS-susceptibility allele (C allele) showed lower enhancer activity for the ZNF512B promoter. Therefore, ZNF512B is presumably lower in those who have the susceptibility allele than in those who have the non-susceptibility allele. ZNF512B over-expression enhanced TGF-b signaling, while its knockdown decreased the signal. Our findings suggest that ZNF512B is an important positive regulator of TGF-b and that lowered ZNF512B expression is implicated in the pathogenesis of ALS susceptibility via decreased TGF-b signal.
In this study, we screened the genic regions using .52 000 gene-based SNPs from the JSNP database. The number of SNPs and their coverage are not sufficient to screen the entire genome. Our study must have many false negatives. Current commercial GWAS platforms are considered superior to ours in terms of the study power and the coverage of SNPs in the human genome. In contrast, the false-positive association of rs2275294 is unlikely. The inflation factor was low and principal component analysis showed no evidence of population stratification. We validated the association in independent Japanese panels. The statistical significance of the association for the combined P-values by two different methods fulfilled criteria of the genome-wide significance level. The results of the two analyses were very similar, which further shows that a hidden confounder in our population is unlikely. In addition, there was no difference in the population structures among the case -control sets by Wright's F statistics (53) throughout the study. The MAF of rs2275294 in 744 Japanese samples deposited in dbSNP is similar to that of our controls (0.414).
In spite of its very significant association in our study, rs2275294 in ZNF512B has not been found in the previous GWASs. Several explanations can be considered. The main reason is that rs2275294 was not included in the platforms of the previous GWASs. Only 15 SNPs in Illumina 610K SNP Array were mapped to the 111 kb genomic region (1 SNP/7.4 kb) corresponding to the ALS critical region we determined. Also, only 10 SNPs in Affymetrix SNP Array 6.0 were mapped to the genomic region (1 SNP/11.1 kb). In addition, rs2275294 is not even mapped in the HapMap JPT database, nor included in the CEU and YRI HapMap data sets. In the Illumina and Affymetrix SNP arrays, the numbers of SNPs in the ZNF512B locus are only two and one, respectively. Their coverages of ZNF512B-SNPs in the ALS critical region were very low, 2/15 (13%) and 1/10 (10%), respectively. The low coverage of the region might have led to the false-negative association in the previous GWASs. No SNP was in strong LD (r 2 . 0.8) with rs2275294 in CHB-JPT, CEU and YRI in the 1000 Genomes data (Supplementary Material, Table S4 ). Hence, we speculate that rs2275294 has been identified by virtue of our platform. Still another explanation is the ethnic difference of ALS susceptibility.
A number of GWASs in ALS have been performed recently. They report the identification of five candidate genes and two candidate loci (30) (31) (32) (33) (34) (35) . Among them, only five gene loci (DPP6, ITPR2, FLJ10986, KIFAP3 and UNC13A) were included in our platform. We checked 16 SNPs in DPP6, 23 in ITPR2, 2 in FLJ10986, 9 in KIFAP3 and 4 in UNC13A; however, their associations were not replicated in our study (Supplementary Material, Table S5 ). The small number of samples and the low coverage of SNPs in our platform may have resulted in false-negative association. Ethnic differences may be another reason for no replication. The 9p21.2 SNP that has been reported in the previous study (42) was not included in the present study. The tested SNPs for previous associations were negative, but no evidence can be provided for the chromosome 9p21.2 locus. Because the powers of Japanese and Chinese were only 0.37 and 0.11, respectively (42), the negative association may be due to a lack of power in the study. More extensive association studies using larger panels of Japanese samples will be required to conclude the associations between previous candidate genes and ALS.
ZNF512B was originally identified as a KIAA1196 in the course of the Kazusa Human cDNA project (56) . The ZNF512B cDNA is 5919 bp long and encodes an 893 amino-acid protein that is ubiquitously expressed in various tissues, including the brain and spinal cord (56). Our immunohistochemical studies confirmed its localization in the spinal cord. The ZNF512B protein showed no significant homology with any proteins in the public database. It contains six C2H2-type zinc finger domains and is predicted to act as a transcription factor. The ALS-susceptibility SNP rs2275294 was localized to intron 12 of ZNF512B. We have demonstrated that the genomic region containing rs2275294 can act as an enhancer of the ZNF512B promoter and that the susceptibility allele of rs2275294 had reduced transcriptional activity, which was likely due to its decreased binding capacity to trans-factors. Further studies for the upstream factors of ZNF512B are necessary to clarify the molecular pathogenesis of ALS related to ZNF512B.
We showed that ZNF512B is a positive regulator of the canonical TGF-b signaling pathway through SMAD2/3. TGF-b signal is essential for the survival of neurons (44 -46) . Upregulation of PAI-1 by SMAD3-dependent induction in astrocytes mediates the neuroprotective activity of TGF-b against NMDA receptor-mediated excitotoxicity (57) . TGF-b signal has been implicated in the pathogenesis of ALS. Plasma TGF-b1 level is significantly increased in ALS patients compared with healthy controls, and there is a significant positive correlation between TGF-b1 concentration in ALS patients and duration of their disease (58) . A microarray analysis showed a 4.8-fold increased expression of SMAD4 in sALS compared with neurologically normal controls (59) . C and D) . The ZNF512B immuno-reactivity was intense in motor neuron cells in the anterior horn of ALS patients, while it was hardly detectable in those of controls. Glial cells in the anterior horn did not show ZNF512B immuno-reactivity. Scale bar, 100 mm.
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Also, phosphorylated SMAD2/3 immuno-reactivity is increased in the remaining spinal motor neurons and glial cells in sporadic and familial ALSs, as well as in Sod1 transgenic mice (60) . These findings suggest that the TGF-b signal is increased in ALS. Several studies have shown an association between duration of ALS and TGF-b levels. Houi et al. (58) found a positive correlation between the plasma concentration of TGF-b1 in ALS patients and the duration of disease. Another group reported that TGF-b1 concentrations in serum and cerebrospinal fluid did not differ between ALS patients and controls, but were higher in ALS patients with a terminal clinical status than in controls (61) . These data suggest that TGF-b is increased in the motor neuron cells of ALS patients during the disease process. As ZNF512B is a critical enhancer of TGF-b signaling, its genetic association may be related to the progression of the disease rather than its onset.
We have demonstrated the localization of ZNF512B in the spinal cord of ALS patients, and that ZNF512B expression in the motor neurons of ALS patients was significantly increased compared with that of controls (Fig. 4) . It is biologically plausible that ZNF512B is a positive regulator (co-activator) of neuroprotective TGF-b signaling (Fig. 3) and may act as a protector against ALS. Taken together with the results of luciferase assay and EMSA that showed allelic differences in ZNF512B expression level (Fig. 2) , a patient harboring the susceptibility allele would have decreased ZNF512B expression level compared with a patient harboring nonsusceptibility alleles. The decreased ZNF512B enhancer activity by the susceptibility allele leads to insufficient increase in ZNF512B, which leads to insufficient increase in the TGF-b signal that results in decreased potential for survival and/or recovery of motor neurons. The discovery of this ALS-susceptibility gene and its pathway should shed light on ALS pathogenesis and facilitate development of targeted therapies.
MATERIALS AND METHODS
Subjects
A total of 1305 ALS patients diagnosed as having probable, probable and laboratory-supported, or definite ALS according to the El Escorial revised criteria (62) were included in the study. All subjects were unrelated Japanese individuals. We obtained a total of 703 DNA samples from the Biobank Japan project (63) . All patients were screened for mutations in SOD1, TARDBP and ANG and none was detected. The mean age of cases was 60.8 years (range: 28-82 years), and 66.1% were male. 74.4% had a spinal onset, 19.6% a bulbar one and 6% a multiple and the others. We obtained a total of 602 DNA samples from the Japanese Consortium for Amyotrophic Lateral Sclerosis Research (JaCALS), Jichi Medical University and The University of Tokyo. The mean age was 61.5 years (range: 27-89 years), and 62.0% were male. 70.4% of the patients had a spinal onset and the remaining had a bulbar one. We recruited 4244 controls through several medical institutes in Japan. Their mean age was 66.8 years (range: 18-98 years), and 48.0% were male. All controls had negative medical and family histories for neurodegenerative disorders. Written informed consent was obtained from all the subjects. The ethical committees at the participating institutions approved this project.
SNP genotyping
Using standard protocols, genomic DNA was extracted from the peripheral blood leukocytes. SNPs were genotyped using the multiplex PCR-based invader assay (Third Wave Technologies) as described previously (64) . A total of 52 608 genebased SNPs were selected from the JSNP database on the basis of the haplotype block structure reported previously (43, 65) . We calculated the total number of independent SNPs in this study to be 43 052 (the SNPs in LD: r 2 . 0.80 were considered as one SNP). We checked the cryptic relatedness for each pair of samples by identity-by-state by estimating the average number of shared alleles between two individuals (V I ) using 48 884 autosomal SNPs. Six individuals in controls were related (V I . 1.65). They were excluded from the analysis. A stepwise screening method was adopted to increase the statistical power (66) . In stage 1, 92 ALS and 233 control subjects were analyzed. We applied the SNP quality control filters of call rate of ≥0.95 in both cases and controls and P-value of Hardy-Weinberg equilibrium (HWE) test of ≥1.0 × 10 22 in controls. A total of 48 939 SNPs on autosomal chromosomes passed the quality control filters and were analyzed for the association. The data of this study are available at the JSNP database (http://snp.ims.u-tokyo.ac.jp/). Among the SNPs analyzed in stage 1, 893 SNPs showing the smallest P-values (0.01 or smaller) were selected for stage 2. Three models (i.e. allelic, dominant and recessive) were tested for the association. Since these three models are not independent, 893 SNPs were isolated. In stage 2, we genotyped an additional 1087 subjects consisting of 362 ALS cases and 725 controls. Stage 1 and stage 2 were defined as the discovery series of this research and the following sample sets were defined as sample set 1 and sample set 2.
SNP discovery
Appropriate genome sequences were extracted from the UCSC Genome Bioinformatics website. The critical region contained five genes (ZNF512B, SAMD10, PRPF6, SOX18 and part of UCKL1) and two non-protein-coding RNAs (UCKL1OS and NCRNA00176). We defined the exonintron boundaries of each gene and designed PCR primer sets for the critical region except for repetitive sequence regions. Each PCR was performed with 5 ng of mixed genomic DNA derived from three ALS subjects; 16 mixed samples were amplified in the GeneAmp PCR system 9700 (PE Applied Biosystems) under the following conditions: initial denaturation at 958C for 2 min, followed by 35 cycles of denaturation at 968C for 30 s, annealing at 60-658C for 30 s, extension at 728C for 2 min and postextension at 728C for 7 min. PCR products served as templates for direct sequencing by the fluorescent dye-terminator cycle sequencing method.
Statistical analysis
For general statistical analyses, we used R statistical environment version 2.6.1 and programs created by our group. The Chi-square test or Fisher's exact test was applied to a two-by-two contingency table in three genetic models: an allele frequency model, a dominant-effect model and a recessive-effect model. Principal component analysis was performed using the smartpca program (52) . We calculated the association in case -control status of stage 1 by using a twstats of EIGENSOFT (52) . The top six principal components were associated with case-control status. Genotype data from the HapMap project were used (67) to estimate the population structure. The significance of stratification was determined using the Wright method (53) . The MantelHaenszel method was used for meta-analysis. An automated laboratory system and bar-coding were employed to reduce clerical errors. The accuracy of our system has been guaranteed in data of the HapMap project (67) . We checked HWE and personally retyped some SNPs from genome screening in duplicated samples. We also obtained age-and genderadjusted odds ratios by logistic regression analysis by program R. Haploview 4.1 was used to infer the LD structure of the ALS critical region. An LD pattern was created based on the JPT HapMap data. Luciferase assay data were analyzed by Student's t-test.
Luciferase assay
We cloned DNA fragments containing rs2275294, nucleotides (nts) 190-208 of intron 12 of ZNF512B. The fragments for both alleles as three tandem copies were inserted into pGL3-Basic vector (Promega) upstream of its luciferase gene in 5 ′ -.3 ′ orientation together with the ZNF512B core promoter of nts 2820 to 274 of its 5 ′ flanking region. We transfected SK_N_Be(2)C cells with 400 ng of each reporter construct using FuGene 6 transfection reagent (Roche) together with 8 ng of pRL-TK vector (Promega) as a control. After 24 h, the cells were lysed in a passive lysis buffer and luciferase activities were measured using Dual-Luciferase Reporter Assay System (Toyo Ink). The entire coding sequence of ZNF512B was cloned into pcDNA3.1, which had a Myc-tag sequence. We also co-transfected with SBE4 (four copies of Smad Binding Element) luciferase reporter vector (55)/Myctagged ZNF512B or SBE 4 -luciferase reporter vector/Myc-tagged pcDNA3.1, and pRL-TK vector using Trans-IT LT reagent (TAKARA Bio). After 24 h, we treated the cells with 10 ng/ml of TGF-b for 24 h. The cells were lysed in a passive lysis buffer and luciferase activities were measured using DualLuciferase Reporter Assay System (Toyo Ink).
Electrophoretic mobility shift assay
A nuclear extract from SK_N_AS cells was prepared as previously described (68) and incubated with oligonucleotides (nts 184 -203 of intron 12 of ZNF512B) that were labeled with digoxigenin-11-ddUTP using the Dig Gel Shift Kit (Roche). The reaction was carried out at a room temperature with an additional 1 mg/ml of poly[d(I-C)]. For the competition assay, the nuclear extract was pre-incubated with unlabeled oligonucleotides (200-fold molar excess) before adding digoxigenin-labeled oligonucleotide. The protein -DNA complex was separated on a non-denaturing 6% polyacrylamide gel in 0.25× Tris-borate-EDTA buffer. We transferred the gel to membrane and detected the signal with a chemiluminescent detection system (Roche) according to the manufacturer's instructions.
RNAi experiment
Double-strand stealth RNAi oligonucleotides (ZNF512B-S183866 for ZNF512B and negative universal control medium GC duplex for negative control) were purchased from Invitrogen. The RNAi oligonucleotides were transfected into a cell line using Lipofectamine RNAiMAX reagent according to the manufacturer's instructions (Invitrogen). After 24 h, we also transfected with SBE 4 -luciferase reporter vector and pRL-TK vector. We treated the cells with TGF-b (10 ng/ml) for 24 h, collected the cells and measured luciferase activity using the Dual-Luciferase Reporter Assay System (Toyo Ink).
Immuno-histochemistry
Autopsy specimens of lumbar spinal cord were obtained from clinically and histopathologically diagnosed ALS patients (13 males and 9 females, age 41-79 years) and from neurologically normal patients (4 males and 3 females, age 42-76 years). The autopsy times in relation to death for the cases and controls (average + SD) were 4.0 + 2.8 h and 4.5 + 5.2 h, respectively. 6-mm-thick sections were prepared from paraffin-embedded tissues. The sections were microwaved for 20 min in 50 mM citrate buffer (pH 6.0) and then treated with a TNB blocking buffer (PerkinElmer) before incubation with an anti-ZNF512B antibody (Santa Cruz Biotechnology, 1:200). The immuno-reactivity was detected using EnVision+ System-HRP (Dako). The sections were photographed with an optical microscope (BX51, Olympus).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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